Geode Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,629,759
| Closed | -$15.6M | – | 4565 |
|
|
2024
Q4 | $15.6M | Buy |
1,629,759
+12,622
| +0.8% | +$65.9K | ﹤0.01% | 2091 |
|
|
2024
Q3 | $4.63M | Sell |
1,617,137
-5,438
| -0.3% | -$16.8K | ﹤0.01% | 2797 |
|
|
2024
Q2 | $4.74M | Buy |
1,622,575
+59,215
| +4% | +$162K | ﹤0.01% | 2758 |
|
|
2024
Q1 | $4.99M | Buy |
1,563,360
+40,305
| +3% | +$134K | ﹤0.01% | 2707 |
|
|
2023
Q4 | $5.12M | Buy |
1,523,055
+104,738
| +7% | +$270K | ﹤0.01% | 2695 |
|
|
2023
Q3 | $3.38M | Buy |
1,418,317
+193,750
| +16% | +$406K | ﹤0.01% | 2843 |
|
|
2023
Q2 | $2.16M | Buy |
1,224,567
+718,477
| +142% | +$1.84M | ﹤0.01% | 3087 |
|
|
2023
Q1 | $1.56M | Buy |
506,090
+14,618
| +3% | +$87.6K | ﹤0.01% | 3137 |
|
|
2022
Q4 | $2.6M | Buy |
491,472
+36,420
| +8% | +$166K | ﹤0.01% | 2941 |
|
|
2022
Q3 | $1.61M | Buy |
455,052
+192,571
| +73% | +$637K | ﹤0.01% | 3160 |
|
|
2022
Q2 | $677K | Sell |
262,481
-240,551
| -48% | -$669K | ﹤0.01% | 3594 |
|
|
2022
Q1 | $2.25M | Buy |
503,032
+12,433
| +3% | +$56.1K | ﹤0.01% | 3205 |
|
|
2021
Q4 | $3.34M | Buy |
490,599
+113,850
| +30% | +$776K | ﹤0.01% | 3114 |
|
|
2021
Q3 | $2.75M | Buy |
376,749
+205
| +0.1% | +$1.76K | ﹤0.01% | 3220 |
|
|
2021
Q2 | $3.77M | Sell |
376,544
-26,249
| -7% | -$235K | ﹤0.01% | 3064 |
|
|
2021
Q1 | $3.85M | Buy |
402,793
+189,886
| +89% | +$1.86M | ﹤0.01% | 2911 |
|
|
2020
Q4 | $2.33M | Buy |
212,907
+24,067
| +13% | +$254K | ﹤0.01% | 3000 |
|
|
2020
Q3 | $1.68M | Buy |
+188,840
| New | +$2.15M | ﹤0.01% | 2965 |
|
Other funds holding PSTX
Geode Capital Management's PSTX Position: Q1 2025 in Review
Geode Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 1,629,759 shares — an estimated $15.6M sold.
Geode Capital Management first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $15.6M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Geode Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Geode Capital Management sold 1,629,759 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $15.6M.
- Geode Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Geode Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $15.6M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.